NewsBenzinga아이오밴스의 2상 라이필루셀+펨브롤리주맙, 1차 치료 진행성 흑색종에서 62.5% ORR 및 29.2% 완전반응률 달성, 50.9개월 시점에서 중앙 생존기간 미도달 아이오밴스의 2상 라이필루셀+펨브롤리주맙, 1차 치료 진행성 흑색종에서 62.5% ORR 및 29.2% 완전반응률 달성, 50.9개월 시점에서 중앙 생존기간 미도달 Benzinga 2026.10.23 14:18 (GMT+0) Open on Benzinga Other news Airbnb Co-Founder Joe Gebbia Says He Modernized Federal Retirement System In 6 Months for $1.5 Million After Contractors Spent $100 Million NVIDIA's Jensen Huang Crisis Threatens to Rewrite the Rules of the AI Boom Mondelez's Multi-Million Portfolio Shift: Unloads French Bakery and Cereal Bars Business Ur-Energy Begins Fieldwork For Baseline Studies At Its Lost Solider Project; Will Take Construction Decision For Potential Third Mine After Technical Report Alibaba Is Facing a Perfect Storm, and Q2 Earnings Won’t Be a Magical Fix for BABA Stock CME Stock: Is Wall Street Bullish or Bearish?
Airbnb Co-Founder Joe Gebbia Says He Modernized Federal Retirement System In 6 Months for $1.5 Million After Contractors Spent $100 Million
Ur-Energy Begins Fieldwork For Baseline Studies At Its Lost Solider Project; Will Take Construction Decision For Potential Third Mine After Technical Report